Table of Contents
Hyderabad, India—Sai Life Sciences Limited, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the inauguration of a state-of-the-art Peptide Research Center at its integrated R&D campus in Hyderabad.
Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, announced the launch: “As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.”
The Peptide Research Center is designed to support pharmaceutical and biotech innovators with specialized services spanning peptide synthesis, discovery, and advanced modalities, including complex conjugates. Equipped with automation, advanced liquid handling, robotics, and high-throughput systems, the facility enhances peptide-based therapeutic development's precision, scalability, and efficiency.
Maneesh Pingle, Head of Discovery Services at Sai Life Sciences, commented: “The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients’ evolving needs as they advance peptide therapies across diverse therapeutic areas.”
The new research center seamlessly integrates with Sai Life Sciences’ end-to-end discovery services, covering synthetic and medicinal chemistry, biology, DMPK, and toxicology. This comprehensive approach ensures smooth transitions between different drug discovery stages, accelerating development timelines and improving success rates for peptide-based drugs.
Sai Life Sciences is an innovator-focused CRDMO that collaborates with over 300 global pharma and biotech companies to accelerate the discovery, development, and commercialization of new chemical entity (NCE) small molecule programs. Over the past 25 years, the company has successfully supported various programs, consistently delivering high-quality and responsive services. Sai Life Sciences employs over 3,000 professionals in India, the UK, the USA, and Japan. For more information, visit www.sailife.com.
